公开(公告)号：US11701419B2

公开(公告)日：2023-07-18

申请号：US16841485

申请日：2020-04-06

Applicant: Boehringer Ingelheim Animal Health USA Inc. ,  Iowa State University Research Foundation, Inc.

Inventor： Arun Iyer ,  Luis Alejandro Hernandez ,  Abby Patterson ,  Bailey Arruda ,  Luis Gabriel Gimenez-Lirola ,  Dave Michael Anstrom ,  Eric M. Vaughn ,  Pablo E. Pineyro Pineiro ,  Troy James Kaiser ,  Joseph Ralph Hermann

IPC: A61K39/12 ,  A61K39/23 ,  A61P31/20 ,  A61P37/04 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K39/23 ,  A61P31/20 ,  A61P37/04 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2750/10034 ,  C12N2750/10071 ,  C12N2750/14034

Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 3 (PCV3) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV3 infection.

公开(公告)号：US09228242B2

公开(公告)日：2016-01-05

申请号：US12861378

申请日：2010-08-23

Applicant: Xiang-Jin Meng ,  Yaowei Huang

Inventor： Xiang-Jin Meng ,  Yaowei Huang

IPC: C12N15/33 ,  A61K39/12 ,  C12N15/70 ,  C12N1/21 ,  C12N7/00 ,  C12Q1/70 ,  C07K14/005 ,  C07K16/08 ,  G01N33/569 ,  A61K39/00

CPC classification number: G01N33/56983 ,  A61K39/12 ,  A61K2039/552 ,  C07K14/005 ,  C07K16/081 ,  C12N7/00 ,  C12N2750/00021 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/14034 ,  C12Q1/701 ,  G01N2333/01 ,  G01N2333/085 ,  G01N2469/20

Abstract: The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies.

Abstract translation: 本发明提供了含有编码猪扭转腱病毒（PTTV）基因型或亚型PTTV1a-VA，PTTV1b-VA，PTTV2b-VA和PTTV2c-VA的多核酸分子的四种纯化制剂。 本发明还提供感染性DNA克隆，含有该感染性核酸基因组分子的生物功能质粒或病毒载体。 本发明进一步提供活的，减毒的载体表达和纯化的重组衣壳亚单位或灭活的病毒疫苗以防止PTTV感染。 本发明另外提供了包含PTTV特异性基因产物的亚单位疫苗，特别是用于保护免受PTTV感染的ORF1衣壳基因产物。 此外，本发明提供了使用PTTV1，PTTV2和个体PTTV1基因型的特异性引物通过聚合酶链反应（PCR）诊断PTTV感染的方法。 最后，本发明提供了通过免疫学方法诊断PTTV感染的方法，例如使用PTTV特异性抗原检测血清PTTV特异性抗体的酶联免疫吸附测定（ELISA）和蛋白质印迹。

公开(公告)号：US08227583B2

公开(公告)日：2012-07-24

申请号：US12211174

申请日：2008-09-16

Applicant: Sanjay Kapil ,  Emily Cooper

Inventor： Sanjay Kapil ,  Emily Cooper

IPC: C07H23/00

CPC classification number: A61K39/23 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/14022 ,  C12N2750/14032 ,  C12N2750/14034 ,  C12N2750/14043 ,  C12N2750/14051 ,  C12N2750/14071 ,  C12N2750/14334 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2333/015

Abstract: Canine parvovirus vaccines and diagnostics and methods for their use are provided.

公开(公告)号：US20090162837A9

公开(公告)日：2009-06-25

申请号：US11038682

申请日：2005-01-19

Applicant: Herve Poulet ,  Denis Barral

Inventor： Herve Poulet ,  Denis Barral

IPC: C12Q1/70 ,  C12Q1/68

CPC classification number: A61K39/118 ,  A61K38/00 ,  A61K39/12 ,  A61K39/125 ,  A61K2039/522 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16663 ,  C12N2710/16734 ,  C12N2710/24043 ,  C12N2740/13034 ,  C12N2750/14034 ,  C12N2750/14063 ,  C12N2770/16034 ,  C12N2770/16063

Abstract: The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention.

Abstract translation: 本发明涉及改进的灭活的猫杯状病毒（FCV）疫苗。 本发明还提供了在制备FCV免疫原性组合物中制备稳定的灭活FCV的方法和使用这种稳定的灭活的FCV。 本发明进一步提供使用本发明的免疫原性组合物在猫科动物中诱导免疫应答的方法，优选猫。

公开(公告)号：US20070098744A1

公开(公告)日：2007-05-03

申请号：US11544120

申请日：2006-10-06

Applicant: Ruth Knorr ,  Christoph Cavadini ,  Jalil Benyacoub ,  Ebenezer Satyaraj

Inventor： Ruth Knorr ,  Christoph Cavadini ,  Jalil Benyacoub ,  Ebenezer Satyaraj

IPC: A61K39/02

CPC classification number: C12R1/01 ,  A23K10/18 ,  A23K20/168 ,  A23K20/184 ,  A23K50/40 ,  A23K50/48 ,  A23L33/135 ,  A61K31/5685 ,  A61K35/744 ,  A61K39/12 ,  A61K39/125 ,  A61K39/23 ,  A61K39/245 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2750/14034 ,  C12N2770/16034 ,  C12R1/46

Abstract: Compositions and methods for modulating immunity and vaccine efficacy in animals are disclosed. The compositions and methods utilize probiotic organisms, specifically probiotic Enterococcus strains, and are particularly applicable to felines.

Abstract translation: 公开了调节动物免疫力和疫苗功效的组合物和方法。 组合物和方法利用益生菌，特别是益生菌肠球菌菌株，特别适用于猫科动物。

公开(公告)号：US5124148A

公开(公告)日：1992-06-23

申请号：US744438

申请日：1991-08-13

Applicant: Laszlo K. Csatary ,  Richard J. Massey

Inventor： Laszlo K. Csatary ,  Richard J. Massey

IPC: A61K35/76 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K39/17 ,  A61K39/295

CPC classification number: A61K39/17 ,  A61K35/76 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/58 ,  A61K2039/585 ,  A61K2039/70 ,  C12N2710/16334 ,  C12N2710/16734 ,  C12N2720/10032 ,  C12N2720/10034 ,  C12N2750/14034 ,  C12N2760/18132 ,  C12N2760/18134 ,  C12N2760/18734 ,  C12N2760/20134 ,  C12N2770/20034 ,  C12N2770/32034

Abstract: A method for treating human disease of viral etiology which employs the administration of a pharmaceutically effective amount of a live attenuated virus. Avian paramyxovirus is the virus preferred for use in live attenuated vaccine form, although other viruses of human and nonhuman origin have also been shown to be effective. The administration of a pharmaceutically effective amount of avian paramyxovirus and avian rotavirus vacciine has been shown to be efficacious in the treatment of Herpes virus infections, hepatitis-A, some cancers, aphthous stomatitis, acquired immune deficiency syndrome (AIDS) and polyarteritis nodosa.

Abstract translation: 一种用于治疗病毒性病毒的人类疾病的方法，其使用药物有效量的活减毒病毒。 禽副粘病毒是优选用于减毒活疫苗的病毒，尽管人类和非人来源的其他病毒也被证明是有效的。 药物有效量的禽副粘病毒和禽类轮状病毒vacciine的施用已被证明在治疗疱疹病毒感染，甲型肝炎，一些癌症，口疮性口炎，获得性免疫缺陷综合征（AIDS）和结节性多动脉炎方面是有效的。

公开(公告)号：US20180214538A1

公开(公告)日：2018-08-02

申请号：US15892247

申请日：2018-02-08

Applicant: SILLAJEN BIOTHERAPEUTICS, INC. ,  SILLAJEN, INC.

Inventor： David KIRN ,  John BELL ,  Caroline BREITBACH ,  Anne MOON ,  Tae-Ho HWANG ,  Yu Kyoung LEE ,  Mi-kyung KIM

IPC: A61K39/285 ,  A61K35/26

CPC classification number: A61K39/285 ,  A61K35/26 ,  A61K35/76 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/125 ,  A61K39/145 ,  A61K39/165 ,  A61K39/17 ,  A61K39/205 ,  A61K39/235 ,  A61K39/245 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55522 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/734 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/16632 ,  C12N2710/16634 ,  C12N2710/24034 ,  C12N2710/24132 ,  C12N2720/12232 ,  C12N2750/14034 ,  C12N2760/16034 ,  C12N2760/18134 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20034 ,  C12N2760/20232 ,  C12N2770/32034 ,  C12N2770/32334 ,  C12N2770/36034 ,  G01N33/574

Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

公开(公告)号：US09839613B2

公开(公告)日：2017-12-12

申请号：US15024226

申请日：2014-09-26

Applicant: Intervet Inc.

Inventor： Zhisong Qiao ,  Kevin O'Connell

IPC: A61K9/16 ,  C12N7/00 ,  A61K39/155 ,  A61K39/23 ,  A61K39/175 ,  A61K39/235 ,  A61K39/295 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K9/1623 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1658 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K39/235 ,  A61K39/295 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10334 ,  C12N2710/10371 ,  C12N2750/14034 ,  C12N2750/14071 ,  C12N2750/14322 ,  C12N2750/14334 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18434 ,  C12N2760/18471

Abstract: The present invention discloses dry formulations of room temperature stable vaccines that comprise a live attenuated virus, a sugar stabilizer, and an amino acid stabilizer. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.

公开(公告)号：US09526780B2

公开(公告)日：2016-12-27

申请号：US14422846

申请日：2013-08-16

Applicant: Intervet Inc.

Inventor： Zhisong Qiao ,  Kevin O'Connell

IPC: A61K39/235 ,  A61K39/155 ,  A61K39/23 ,  A61K39/02 ,  A61K9/08 ,  A61K47/42 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K39/175 ,  C12N7/00 ,  A61K47/20 ,  A61K47/22 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/235 ,  A61K9/08 ,  A61K39/0225 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K47/10 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2750/14034 ,  C12N2750/14322 ,  C12N2760/18034 ,  C12N2760/18434 ,  C12N2760/18634

Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.

公开(公告)号：US20160228369A1

公开(公告)日：2016-08-11

申请号：US15024226

申请日：2014-09-26

Applicant: Intervet International B.V. ,  Intervet Inc.

Inventor： Zhisong Qiao ,  Kevin O'Connell

IPC: A61K9/16 ,  C12N7/00 ,  A61K39/155 ,  A61K39/23 ,  A61K39/175 ,  A61K39/235

CPC classification number: A61K9/1623 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1658 ,  A61K39/12 ,  A61K39/155 ,  A61K39/175 ,  A61K39/23 ,  A61K39/235 ,  A61K39/295 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10334 ,  C12N2710/10371 ,  C12N2750/14034 ,  C12N2750/14071 ,  C12N2750/14322 ,  C12N2750/14334 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18434 ,  C12N2760/18471

Abstract: The present invention discloses dry formulations of room temperature stable vaccines that comprise a live attenuated virus, a sugar stabilizer, and an amino acid stabilizer. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.

Abstract translation: 本发明公开了包含活减毒病毒，糖稳定剂和氨基酸稳定剂的室温稳定疫苗的干燥制剂。 本发明还公开了通过这种疫苗的施用来制备这种疫苗和保护动物的方法。